is an IP litigation partner focusing on high-stakes trade secrets matters and life sciences patent litigation, particularly in the pharmaceutical industry, diagnostics and the emerging fields of precision medicine and cell and gene therapy. His previous case experience covers a broad range of technical fields, including oncology, molecular diagnostics and biostatistics, often involving issues at the cutting-edge of the law, notably in relation to second medical-use patents. Daniel frequently comments on life sciences and IP topics and is regarded as a thought leader on CRISPR gene editing. He is active as a member of AIPPI and EPLAW, including as vice-chair of AIPPI’s standing committee on biotechnology.
Chambers and Partners make no representation or endorsement of the quality and services supplied
by companies or firms that may be found on this website. In no event will Chambers and Partners
be liable for any damages including, without limitation, indirect or consequential damages,
or any damages whatsoever arising from use or loss of use, data, or profits, whether in action
of contract, negligence or other tort action, arising out of or in connection with the use
of the website.